Home Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
 

Keywords :   


Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play

2016-03-02 23:40:43| Biotech - Topix.net

I first bought and wrote about Portola Pharmaceuticals in mid-2014, when the stock was revisiting its brief peak around $30 that it first hit in September 2013. It had IPO'ed in May at $15, so Friday's closing price of $27.79 still represents a successful IPO.

Tags: business play reports analysis

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
25.06New model Is transforming the study of liver abscesses in cattle
25.06Royal Mail buyer to make offer for all staff shares
More »